雷普里根 RGEN 深 沪
已收盘 02-06 16:00:00 美东时间
142.18
+2.520
+1.80%
华盛通- 最 高145.59
- 今 开142.08
- 成交量 86.59万股
- 最 低 139.80
- 昨 收 139.66
- 总市值 80.03亿
- 52周最高 175.77
- 市盈率 静 --
- 换手率 1.54%
- 52周最低 102.965
- 委 比 32.56%
- 总股本 5629.07万
- 历史最高 327.32
- 量 比 1.04
- 振 幅 4.15%
- 历史最低 2.90
- 每 手 1
- 风险率 17.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
Expert Outlook: Repligen Through The Eyes Of 5 Analysts
In the preceding three months, 5 analysts have released ratings for Repligen (N...
01-17 04:00
UBS Maintains Buy on Repligen, Raises Price Target to $200
UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $190 to $200.
01-17 02:00
Repligen Appoints Martin D. Madaus Board Chair, Effective March 13, Succeeding Tony Hunt
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026.
01-06 20:31
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
Repligen Corporation announced that Dr. Martin D. Madaus has been elected Chair of the Board, effective March 13, 2026, succeeding Tony Hunt, who is retiring as Executive Chair. Hunt will serve as an advisor until March 2027. Repligen President and CEO Olivier Loeillot praised Hunt’s decade of service and highlighted Madaus’s expertise in bioprocessing and biopharma. Madaus, with over 36 years of industry experience, including leadership at Milli...
01-06 12:30
Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
Repligen Corporation announced its participation in the J.P. Morgan 2026 Healthcare Conference in San Francisco from January 12-15, 2026. Olivier Loeillot, President and CEO, will present on January 13 at 2:15 p.m. PT. A live webcast of the presentation will be available on Repligen’s Investor Relations website, www.repligen.com, with a limited replay period. Repligen, a global life sciences company, focuses on innovative bioprocessing technologi...
2025-12-18 12:30
Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows
Repligen Corporation launched three new high-performance chromatography resins: AVIPure® HiPer™ AAV9 and AAV8 affinity resins, and HiPer™ QA anion exchange resin. These products, built on the Tantti™ DuloCore™ base bead technology, are designed for next-generation bioprocessing, particularly for viral vector applications. They aim to accelerate gene therapy development, enhance molecule stability, and improve process efficiency. This expansion re...
2025-12-16 12:30
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
Wells Fargo Maintains Overweight on Repligen, Raises Price Target to $190
Wells Fargo analyst Brandon Couillard maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $175 to $190.
2025-12-16 02:29
Repligen Corporation to Present at Evercore Healthcare Conference
Repligen Corporation will participate in the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida, from December 2-4. Jason Garland, CFO, will join an analyst-led discussion on December 3 at 1:20 p.m. ET. A live webcast will be available via Repligen’s Investor Relations website at www.repligen.com, with a limited replay option post-event. Repligen, a global life sciences company, specializes in bioprocessing technologies for biolog...
2025-11-26 12:30
